Background: Dialysis and kidney transplant patients are vulnerable populations for COVID-19 related disease and mortality.
Methods: We conducted a prospective study exploring the eight week time course of specific cellular (interferon-γ release assay and flow cytometry) or/and humoral immune responses (ELISA) to SARS-CoV-2 boost vaccination in more than 3100 participants including medical personnel, dialysis patients and kidney transplant recipients using mRNA vaccines BNT162b2 or mRNA-1273.
Results: SARS-CoV-2-vaccination induced seroconversion efficacy in dialysis patients was similar to medical personnel (> 95%), but markedly impaired in kidney transplant recipients (42%). T-cellular immunity largely mimicked humoral results. Major risk factors of seroconversion failure were immunosuppressive drug number and type (belatacept, MMF-MPA, calcineurin-inhibitors) as well as vaccine type (BNT162b2 mRNA). Seroconversion rates induced by mRNA-1273 compared to BNT162b2 vaccine were 97% to 88% ( < 0.001) in dialysis and 49% to 26% in transplant patients, respectively. Specific IgG directed against the new binding domain of the spike protein (RDB) were significantly higher in dialysis patients vaccinated by mRNA-1273 (95%) compared to BNT162b2 (85%, < 0.001). Vaccination appeared safe and highly effective demonstrating an almost complete lack of symptomatic COVID-19 disease after boost vaccination as well as ceased disease incidences during third pandemic wave in dialysis patients.
Conclusion: Dialysis patients exhibit a remarkably high seroconversion rate of 95% after boost vaccination, while humoral response is impaired in the majority of transplant recipients. Immunosuppressive drug number and type as well as vaccine type (BNT162b2) are major determinants of seroconversion failure in both dialysis and transplant patients suggesting immune monitoring and adaption of vaccination protocols.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299287 | PMC |
| http://dx.doi.org/10.1016/j.lanepe.2021.100178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case of COVID-19 infection-induced complement-mediated thrombotic microangiopathy.
Med J Armed Forces India
December 2024
Senior Advisor (Medicine) & Nephrologist, Base Hospital Delhi Cantt, New Delhi, India.
The SARS-CoV-2 virus can cause thrombotic microangiopathy (TMA) by alternate pathway activation. We present a case of a young female patient who presented with fever and dialysis-dependent acute kidney injury. On evaluation, she was diagnosed with COVID-19-induced complement-mediated thrombotic microangiopathy (CM-TMA).
View Article and Find Full Text PDFAnesthesia management using remimazolam for coronary artery bypass grafting and aortic valve replacement in a patient with severe cardiac dysfunction: A case report.
SAGE Open Med Case Rep
December 2024
Department of Anesthesiology, Showa University School of Medicine, Tokyo, Japan.
Remimazolam, a short-acting benzodiazepine approved for use in general anesthesia in Japan in 2020, has cardiovascular stability superior to conventional anesthetics. Anesthesia management using remimazolam of a patient with impaired cardiac function and several complications is reported. A man in his 50s with hypertension, diabetes mellitus, and chronic kidney disease (G 5) on dialysis came to our hospital with a chief complaint of exertional dyspnea and chest tightness, and a close examination showed stenoses of three coronary arteries.
View Article and Find Full Text PDFHandgrip strength and body mass index exhibit good predictive value for sarcopenia in patients on peritoneal dialysis.
Front Nutr
December 2024
School of Nursing, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Aim: The diagnosis of sarcopenia in patients on peritoneal dialysis (PD) in clinics is limited owing to its relatively complicated process and the need for expensive assessment equipment. This study aimed to develop and validate sex-specific nomogram models based on body mass index (BMI), handgrip strength, and other routine follow-up examination indicators to predict sarcopenia in patients on PD.
Methods: From March 2023 to February 2024, 699 eligible patients were recruited from the PD centers of two tertiary hospitals in southeastern China.
The role of acetazolamide in critical care and emergency medicine.
J Geriatr Cardiol
November 2024
Geriatric Medicine Residency Program, University of Rome "Tor Vergata", Rome, Italy.
Acetazolamide is the commonly prescribed oral and intravenous carbonic anhydrase inhibitor; over the years, its use in clinical practice has decreased in favor of more recent drugs. However, it is a rather handy drug, which can be useful in several clinical settings when managing critically ill patients. The objective of this review is the evaluation of the most recent evidence on the use of acetazolamide in emergency medicine and critical care medicine.
View Article and Find Full Text PDFMajor Perioperative Bleeding in Patients on Dialysis Undergoing Nonelective Abdominal Surgeries.
J Surg Res
December 2024
The Warren Alpert Medical School of Brown University, Providence, Rhode Island; Department of Surgery, Cambridge Health Alliance, Cambridge, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address:
Introduction: Patients with end-stage renal disease (ESRD) are at increased risk for bleeding complications following surgery. However, the approach to the preoperative risk assessment and risk reduction, if feasible, in ESRD patients undergoing nonelective abdominal surgery has not been comprehensively studied. We aim to determine the prevalence and risk factors for perioperative bleeding in patients on dialysis undergoing nonelective abdominal surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!